DrugPatentWatch Database Preview
Antares Pharma Inc Company Profile
» See Plans and Pricing
What is the competitive landscape for ANTARES PHARMA INC, and when can generic versions of ANTARES PHARMA INC drugs launch?
ANTARES PHARMA INC has three approved drugs.
There are twenty US patents protecting ANTARES PHARMA INC drugs.
There are eighty-one patent family members on ANTARES PHARMA INC drugs in fifteen countries.
Summary for Antares Pharma Inc
| International Patents: | 81 |
| US Patents: | 20 |
| Tradenames: | 4 |
| Ingredients: | 3 |
| NDAs: | 3 |
Drugs and US Patents for Antares Pharma Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Antares Pharma Inc | XYOSTED (AUTOINJECTOR) | testosterone enanthate | SOLUTION;SUBCUTANEOUS | 209863-003 | Sep 28, 2018 | RX | Yes | Yes | 8,562,564 | Start Trial | Y | Start Trial | |||
| Antares Pharma Inc | XYOSTED (AUTOINJECTOR) | testosterone enanthate | SOLUTION;SUBCUTANEOUS | 209863-003 | Sep 28, 2018 | RX | Yes | Yes | 10,646,495 | Start Trial | Y | Start Trial | |||
| Antares Pharma Inc | OTREXUP | methotrexate | SOLUTION;SUBCUTANEOUS | 204824-003 | Oct 11, 2013 | RX | Yes | Yes | 8,814,834 | Start Trial | Y | Start Trial | |||
| Antares Pharma Inc | OTREXUP | methotrexate | SOLUTION;SUBCUTANEOUS | 204824-008 | Mar 24, 2016 | RX | Yes | Yes | 9,533,102 | Start Trial | Y | Start Trial | |||
| Antares Pharma Inc | OTREXUP | methotrexate | SOLUTION;SUBCUTANEOUS | 204824-003 | Oct 11, 2013 | RX | Yes | Yes | 9,867,949 | Start Trial | Y | Start Trial | |||
| Antares Pharma Inc | XYOSTED (AUTOINJECTOR) | testosterone enanthate | SOLUTION;SUBCUTANEOUS | 209863-001 | Sep 28, 2018 | RX | Yes | Yes | 10,478,560 | Start Trial | Y | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Antares Pharma Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Antares Pharma Inc | OTREXUP | methotrexate | SOLUTION;SUBCUTANEOUS | 204824-001 | Oct 11, 2013 | RE44847 | Start Trial |
| Antares Pharma Inc | OTREXUP | methotrexate | SOLUTION;SUBCUTANEOUS | 204824-007 | Mar 24, 2016 | RE44846 | Start Trial |
| Antares Pharma Inc | OTREXUP | methotrexate | SOLUTION;SUBCUTANEOUS | 204824-008 | Mar 24, 2016 | RE44846 | Start Trial |
| Antares Pharma Inc | OTREXUP | methotrexate | SOLUTION;SUBCUTANEOUS | 204824-004 | Oct 11, 2013 | 6,746,429 | Start Trial |
| Antares Pharma Inc | OTREXUP | methotrexate | SOLUTION;SUBCUTANEOUS | 204824-004 | Oct 11, 2013 | RE44846 | Start Trial |
| Antares Pharma Inc | OTREXUP | methotrexate | SOLUTION;SUBCUTANEOUS | 204824-005 | Nov 7, 2014 | 6,746,429 | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Antares Pharma Inc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Spain | 2716135 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2010108116 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2009114542 | Start Trial |
| South Korea | 20120028294 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2013012745 | Start Trial |
| European Patent Office | 3636301 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
